0001104659-23-059680.txt : 20230512 0001104659-23-059680.hdr.sgml : 20230512 20230512154324 ACCESSION NUMBER: 0001104659-23-059680 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230510 FILED AS OF DATE: 20230512 DATE AS OF CHANGE: 20230512 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sabba Stephen L CENTRAL INDEX KEY: 0001442372 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33093 FILM NUMBER: 23915281 MAIL ADDRESS: STREET 1: DORSET MANAGEMENT CORP STREET 2: 485 UNDERHILL BLVD SUITE 205 CITY: SYOSSET STATE: NY ZIP: 11791 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LIGAND PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000886163 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770160744 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3911 SORRENTO VALLEY BLVD STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-550-7500 MAIL ADDRESS: STREET 1: 3911 SORRENTO VALLEY BLVD STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 tm2315666-1_4seq1.xml OWNERSHIP DOCUMENT X0407 4 2023-05-10 0 0000886163 LIGAND PHARMACEUTICALS INC LGND 0001442372 Sabba Stephen L DORSET MANAGEMENT CORP 485 UNDERHILL BLVD SUITE 205 SYOSSET NY 11791 1 0 0 0 0 Common Stock 2023-05-10 4 M 0 6408 0.00 A 32192 D Common Stock 2023-05-10 4 S 0 6408 77.1262 D 25784 D Non-Qualified Stock Option (right to buy) 18.82 2023-05-10 4 M 0 6408 0 D 2023-06-11 Common Stock 6408 927 D These securities, as represented in Column 5, include a grant of 1,723 restricted shares approved by the Board of Directors of the Company at the 2022 Meeting ("2022 Shares"), which shares will vest in full on the earlier of (a) the date of the next annual meeting of the Company stockholders following the grant date or (b) on the first anniversary of the grant date. As reported on the Reporting Person's Form 4 dated 14 June 2022, which was filed to reflect the 2022 Meeting grant, the original grant was for 1,004 2022 Shares. The reference to 1,732 2022 Shares reflects certain adjustments by the Company to the 2022 Shares following the Company's 1 November 2022 distribution of a legacy business. The price reported in Column 4 is an average. These shares were sold in separate transactions for the following number of shares and at the respective prices: $77.29 (100), $77.25 (8), $77.23 (41), $77.22 (36), $77.21 (201), $77.20 (372), $77.18 (800), $77.17 (120), $77.16 (34), $77.15 (971), $77.14 (1,305), $77.13 (151), $77.12 (1), $77.11 (239), $77.10 (101), $77.09 (100), $77.08 (1,065), $77.01 (9), and $77.00 (754). This disposition was reported on a Form 144 for filed 10 May 2023. These securities, as represented in Column 5, were acquired by a grant of 7,335 shares approved by the Board of Directors of the Company at the 2013 Meeting, as previously reported on the Reporting Persons Form 4 dated 13 June 2013. That grant vested in full on the first anniversary of the grant date or immediately (x) upon a change in control or a hostile takeover of the Company or (y) the death or permanent disability of the grantee if still serving at that time. By: /s/ Stephen L. Sabba 2023-05-12